Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Carotid Decision Making

12 novembre 2026 aggiornato da: Jesse.A.Columbo, Dartmouth-Hitchcock Medical Center

Improving Shared Decision Making for Older Patients With Carotid Artery Stenosis

Carotid artery stenosis is a common cause of ischemic stroke in the U.S. and disproportionately affects older adults. Patients with carotid artery stenosis face a complex set of decisions when choosing a treatment strategy. Patients must choose among surveillance with medical therapy alone, versus medical therapy plus one of three different procedures. Each treatment option has different levels of evidence to support it, some of which are decades old. Each procedural option has different expected periprocedural courses, different recoveries, and different cardiovascular risks. This challenging decision is amplified among older adults, where decisional values are often different from younger patients traditionally studied in randomized or observational studies. A decision aid could assist patients and providers who are navigating this decision, but no decision aid currently exists that includes all the contemporary carotid artery stenosis treatment options. In addition, as of October 2023, participation in a shared decision-making conversation is a Medicare-mandated component of carotid stenosis care, with reimbursement for procedures predicated on the documentation of the conversation with the patient.

The objective of this project is to conduct a single arm open label trial to test the feasibility of using a paper-based decision aid for patients considering carotid revascularization. The investigators will conduct a feasibility trial using the decision aid on older adults who are considering carotid revascularization. The investigators will recruit 50 participants aged 65 or older from the vascular surgery clinic and administer the decision aid. The investigators will purposively sample at least 10 participants that are age 80 or older. Primary outcomes will center on feasibility, and secondary outcomes will center on decisional conflict and regret.

Panoramica dello studio

Stato

Non ancora reclutamento

Intervento / Trattamento

Descrizione dettagliata

The primary outcomes of this single arm open label feasibility trial are focused on feasibility, and the secondary outcomes will provide data to inform a subsequent R01 study design.

Exposure: The decision aid

Setting: The investigators will sample newly referred and longitudinally treated patients from the Dartmouth Health Vascular Clinic who are being treated for carotid artery stenosis and who are considering carotid revascularization.

Sampling strategy: The investigators will enroll 50 patient-participants. The investigators will review the clinic schedules of the 18 providers each day in clinic and screen them for patients being seen for carotid artery stenosis. The investigators will then discuss with the providers in clinic that day whether any of the patients they are seeing may be considered for carotid revascularization and whether that respective patient would be appropriate for and have the capacity to utilize a decision aid. The investigators will purposively sample a minimum of 10 participants who are aged 80 and older to ensure adequate representation of this age group. Patients with carotid stenosis routinely have a high burden of comorbidities including hypertension, diabetes, coronary disease, kidney disease, and smoking. Patients treated in the Dartmouth Vascular Clinic are representative of this population and will allow us to sample a cohort with multiple comorbidities. Patients meeting the inclusion and exclusion criteria and felt to be appropriate for a decision aid per their treating provider will be approached in clinic to discuss the study.

Statistical analysis:

Outcome 1: The investigators will measure the mean and standard deviation of the time of the clinic visit. The investigators will calculate the visit time from the time of patient check in until the completion of the clinic visit, as assessed by a direct observer. The investigators will compare this to baseline time measurements recorded in the electronic health record for a random sample of 50 carotid stenosis patients meeting the same inclusion / exclusion criteria in the past 3 months.

Outcome 2: The investigators will conduct semi-structured interviews with 10 patients to follow up on the findings from the surveys above. These will be semi-structured interviews that are designed to assess whether the tradeoffs for each decision aid option were understood, and whether they felt that the decision aid helped them reach their choice. The interviews will be recorded and transcribed. The constant comparative method will be used to identify codes inductively. Two independent coders will analyze the data, and then codes will be discussed and data organized. Areas of disagreement will be resolved by consensus, or, if consensus is not possible, by a third independent reviewer. The investigators will organize the codes into key domains through data reduction and interpretation, paying particular attention to the frequency of specific ideas / codes mentioned by participants, and how many participants mentioned them.

The investigators will administer a similar survey to their treating providers within 1 week of the clinic visit. The results of the Likert surveys will be converted to a 5-point scale and the mean and median response will be computed with 95% confidence intervals. The investigators will additionally conduct semi-structured interviews with treating providers to determine feasibility of decision aid use in routine practice.

Secondary outcomes: The investigators will administer a validated decisional conflict scale and decisional regret scale before and after administration of the decision aid. The investigators will use the low literacy version to account for the high prevalence of low literacy in older adults. The investigators will analyze the results according to the validated methods for that survey and compare the before and after results. The investigators will additionally measure the actual treatment decision made by the patient and report this unadjusted. The investigators will finally measure knowledge-based questions that will be administered before and after patients are given the decision aid.

Sample size considerations: For outcome 1, given a sample size of 50 normally distributed outcomes, this will result in sample size with 95% confidence intervals with half widths of 0.32 standard deviation of the matched visit estimates of added time for increasing to 0.34, and 0.36 with 10% and 20% missing data. Similar results hold for the Likert survey in Outcome 3.

Potential pitfalls and alternative strategies: It is possible that it may not be known whether a patient would benefit from a decision aid until the patient receives an imaging study demonstrating the severity of the patient's carotid disease, which may occur just before the patient's clinic visit. Therefore, for patients who are scheduled for a clinic visit but do not have an imaging study, the investigators will ask the vascular laboratory (where the studies are conducted) to notify study personnel once the imaging study is completed.

Tipo di studio

Interventistico

Iscrizione (Stimato)

50

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • New Hampshire
      • Lebanon, New Hampshire, Stati Uniti, 03766
        • Dartmouth Hitchcock Medical Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

65 anni e precedenti (Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patients seen in the outpatient clinic who are considering carotid revascularization versus medical therapy or who were admitted to the hospital and are considering elective carotid revascularization.

Exclusion Criteria:

  • Patients who are considering urgent revascularization, those unable to provide informed consent using the Short Portable Mental Status Questionnaire or those unable to participate in follow-up interview or survey scales due to cognitive reasons.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Decision aid feasibility

Single arm pilot feasibility study of using a decision aid for patients with asymptomatic carotid artery stenosis considering revascularization

The decision aid is paper-based and includes pie charts of perioperative risks and incorporates patient values and preferences about autonomy of decision making.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time to administer the decision aid
Lasso di tempo: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Defined as time from clinic check-in until completion of the visit

Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)
Understanding of the decision aid
Lasso di tempo: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Measured by a knowledge survey

Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Decisional conflict
Lasso di tempo: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Measured using the validated decisional conflict scale

Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)
Decisional regret
Lasso di tempo: Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)

Measured using the validated decisional regret scale

Assessed for up to 2 weeks, from first clinic appointment until the end of the study (5/15/28)
Actual treatment decision made
Lasso di tempo: Assessed for up to 8 weeks

What treatment the patient actually decided on

Assessed for up to 8 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 novembre 2026

Completamento primario (Stimato)

15 maggio 2028

Completamento dello studio (Stimato)

15 maggio 2028

Date di iscrizione allo studio

Primo inviato

2 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Will not share individual patient data due to confidentiality.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi